Vaxfab Enterprises Ltd Board Clears Rs 45 Crore Capital Raise

Issue Size: Rs 45 crore. Face Value: Rs 10 per equity share.

Reader Takeaway: Existing shareholders get a chance to increase stakes, but must await pricing and dilution details later.

What just happened

The Board of Directors of Vaxfab Enterprises Ltd met on October 1, 2026, and officially approved a proposal to raise funds through a rights issue of equity shares. The company plans to raise up to Rs 45 crore through this mechanism, offering equity shares with a face value of Rs 10 each to its existing investor base.

Why this matters

A rights issue is a corporate action that allows existing shareholders to subscribe to additional shares of a company, typically at a price lower than the prevailing market rate. This move by Vaxfab Enterprises is a direct capital-raising exercise. The process is now being managed by a newly constituted Rights Issue Committee, chaired by Mr. Ravindra Ashokbhai Joshi, with Mr. Jinang Dineshkumar Shah and Ms. Juhi Sawajani as members.

What changes now

While the Board has cleared the Draft Letter of Offer, the critical metrics for the investor remain pending. The company has yet to finalize and communicate the record date—the cutoff date for eligibility—the entitlement ratio, and the final issue price. These details are essential for shareholders to calculate the potential dilution of their existing holdings and the cost-benefit of participating in the issue.

What to track next

Investors should keep a close eye on the company's future filings with the BSE. Specifically, the announcements regarding the record date and the final offer price will be the primary indicators for participation. The newly formed Rights Issue Committee is authorized to appoint intermediaries and handle all regulatory filings, so official circulars from this committee will be the primary source for upcoming timelines.